Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769917 | 0.81 | HSD11B1 (0.51) | OPRM1HSD11B1GSK3BALDH1A1SMN1; SMN2 | |
| SCHEMBL19207553 | 0.81 | AKR1C1 (0.52) | OPRM1HSD11B1GSK3BSMN1; SMN2AKR1C1 | |
| SCHEMBL23578123 | 0.77 | GSK3B (0.50) | OPRM1HSD11B1GSK3BAKR1C1 | |
| SCHEMBL4490927 | 0.76 | AKR1C1 (0.55) | OPRM1TPMTAKR1C1 | |
| SCHEMBL1769960 | 0.75 | HDAC4 (0.54) | HSD11B1GSK3BALDH1A1SMN1; SMN2 | |
| SCHEMBL1770012 | 0.75 | HDAC4 (0.58) | HSD11B1GSK3BALDH1A1SMN1; SMN2 | |
| SCHEMBL5643072 | 0.75 | OPRM1 (0.44) | OPRM1SIGMAR1HSD11B1 | |
| SCHEMBL5644252 | 0.75 | OPRM1 (0.42) | OPRM1SIGMAR1HSD11B1TPMTAKR1C1 | |
| SCHEMBL16507538 | 0.74 | AKR1C1 (0.58) | SIGMAR1HSD11B1ALDH1A1SMN1; SMN2AKR1C1 | |
| SCHEMBL5641709 | 0.74 | OPRM1 (0.52) | OPRM1SIGMAR1HSD11B1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1505966-A4 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1505966-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | OPRM1 4713/4885SIGMAR1 3426/4885HSD11B1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.